Literature DB >> 15887119

Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance.

Jamal A Ibdah1, Peter Perlegas, Yiwen Zhao, Jerry Angdisen, Hermina Borgerink, Melanie K Shadoan, Janice D Wagner, Dietrich Matern, Piero Rinaldo, J Mark Cline.   

Abstract

BACKGROUND & AIMS: Little is known about the role of mitochondrial beta-oxidation in development of nonalcoholic fatty liver disease (NAFLD). Mitochondrial trifunctional protein (MTP) catalyzes long-chain fatty acid oxidation. Recently, we generated a mouse model for MTP deficiency and reported that homozygous (MTPa-/-) mice suffer neonatal death. In this study, we investigated effects of heterozygosity for the MTP defect on hepatic oxidative stress, insulin resistance, and development of NAFLD in mice.
METHODS: We evaluated liver histopathology, serum alanine aminotransferase (ALT), glucose, fatty acids, and insulin levels in MTPa+/- and MTPa+/+ littermates. Insulin resistance was evaluated using glucose tolerance test (GTT) and insulin tolerance test (ITT). Liver tissues were used to measure triglyceride and fatty acid content, activity of superoxide dismutases (SOD) and glutathione peroxidase (GPx), glutathione (GSH), and cytochrome P-450 2E1 expression.
RESULTS: Aging but not young MTPa+/- mice developed hepatic steatosis with elevated ALT, basal hyperinsulinemia, and increased insulin area under curve (AUC) on GTT compared with MTPa+/+ littermates. In response to insulin challenge, aging MTPa+/- mice had slower rate of glucose disappearance and increased glucose AUC. Significant hepatic steatosis and insulin resistance developed concomitantly in the MTPa+/- mice at 9-10 months of age. Aging MTPa+/- mice had higher antioxidant activity of total SOD and GPx, lower GSH, and increased expression of cytochrome P-450 2E1, consistent with increased hepatic oxidative stress.
CONCLUSIONS: Heterozygosity for beta-oxidation defects predisposes to NAFLD and insulin resistance in aging mice. Impairment of mitochondrial beta-oxidation may play an important role in pathogenesis of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15887119     DOI: 10.1053/j.gastro.2005.02.001

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  67 in total

1.  Cessation of daily wheel running differentially alters fat oxidation capacity in liver, muscle, and adipose tissue.

Authors:  Matthew J Laye; R Scott Rector; Sarah J Borengasser; Scott P Naples; Grace M Uptergrove; Jamal A Ibdah; Frank W Booth; John P Thyfault
Journal:  J Appl Physiol (1985)       Date:  2008-10-30

2.  Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model.

Authors:  R Scott Rector; John P Thyfault; Grace M Uptergrove; E Matthew Morris; Scott P Naples; Sarah J Borengasser; Catherine R Mikus; Matthew J Laye; M Harold Laughlin; Frank W Booth; Jamal A Ibdah
Journal:  J Hepatol       Date:  2010-03-04       Impact factor: 25.083

Review 3.  Metabolic pathways at the crossroads of diabetes and inborn errors.

Authors:  Eric S Goetzman; Zhenwei Gong; Manuel Schiff; Yan Wang; Radhika H Muzumdar
Journal:  J Inherit Metab Dis       Date:  2017-09-26       Impact factor: 4.982

4.  Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity.

Authors:  Jia Li; Caroline Romestaing; Xianlin Han; Yuan Li; Xinbao Hao; Yinyuan Wu; Chao Sun; Xiaolei Liu; Leonard S Jefferson; Jingwei Xiong; Kathryn F Lanoue; Zhijie Chang; Christopher J Lynch; Huayan Wang; Yuguang Shi
Journal:  Cell Metab       Date:  2010-08-04       Impact factor: 27.287

5.  Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury.

Authors:  John P Thyfault; R Scott Rector; Grace M Uptergrove; Sarah J Borengasser; E Matthew Morris; Yongzhong Wei; Matt J Laye; Charles F Burant; Nathan R Qi; Suzanne E Ridenhour; Lauren G Koch; Steve L Britton; Jamal A Ibdah
Journal:  J Physiol       Date:  2009-02-23       Impact factor: 5.182

6.  Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Authors:  Zvi Ackerman; Mor Oron-Herman; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela; Maria Grozovski
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

Review 7.  Acute fatty liver of pregnancy: an update on mechanisms.

Authors:  Sathish Kumar Natarajan; Kavitha R Thangaraj; Ashish Goel; C E Eapen; K A Balasubramanian; Anup Ramachandran
Journal:  Obstet Med       Date:  2011-07-04

Review 8.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Authors:  Ivana Mikolasevic; Lidija Orlic; Neven Franjic; Goran Hauser; Davor Stimac; Sandra Milic
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

9.  Acetylation of Mitochondrial Trifunctional Protein α-Subunit Enhances Its Stability To Promote Fatty Acid Oxidation and Is Decreased in Nonalcoholic Fatty Liver Disease.

Authors:  Liang Guo; Shui-Rong Zhou; Xiang-Bo Wei; Yuan Liu; Xin-Xia Chang; Yang Liu; Xin Ge; Xin Dou; Hai-Yan Huang; Shu-Wen Qian; Xi Li; Qun-Ying Lei; Xin Gao; Qi-Qun Tang
Journal:  Mol Cell Biol       Date:  2016-09-26       Impact factor: 4.272

10.  New observations on the effect of camellia oil on fatty liver disease in rats.

Authors:  Chun-Xue Li; Li-Rong Shen
Journal:  J Zhejiang Univ Sci B       Date:  2020 Aug.       Impact factor: 3.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.